Nov 04, 2022 15:42 JST

Source: Eisai

Eisai's Sales Subsidiary Collaborates with Thai Life Insurance to Support Access to Treatments for Dementia, Including Alzheimer's Disease, in Thailand

TOKYO, Nov 04, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today that its Thai sales subsidiary Eisai (Thailand) Marketing Co. Ltd. ("Eisai Thailand") made an agreement to collaborate in supporting access to treatments for dementia, including Alzheimer's disease, in Thailand with Thai Life Insurance Public Company Limited, a leading life insurance company in Thailand.

In Thailand, the number of people suffering from dementia is expected to increase significantly from the current 600 thousand to 1.1 million by 2030 due to the rapid aging of the population(1), and the financial burden of the people suffering from dementia, including Alzheimer's disease, and their families due to care is also expected to increase.

With this agreement, Eisai Thailand, together with Thai Life Insurance, which has expertise in the design and development of life and medical insurance products, will work together to design insurance products to cover dementia, including Alzheimer's disease raise awareness of the disease, and build a dementia ecosystem to secure access to next-generation Alzheimer's disease treatments in Thailand.

Eisai believes that it is Eisai's mission to ensure that patients in need have access to its innovative medicines, and will continue to focus on activities for early consultation and diagnosis, as well as development of patient support programs that take into account the healthcare system and income level of each country.

(1) Dementia in the Asia Pacific Region (Alzheimer's Disease International), www.alzint.org/u/Dementia-Asia-Pacific-2014.pdf

Media Inquiries:
Public Relations Department
Eisai Co., Ltd.
+81-(0)3-3817-5120

Source: Eisai
Sectors: BioTech

Copyright ©2024 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


Eisai to Boost Initiatives on Greenhouse Gas Reduction, Aiming to Achieve Net Zero by 2050
February 21 2024 14:26 JST
 
Eisai Selected for 'Human Capital Leaders 2023' and 'Human Capital Management Gold Quality', Recognized as Company Committed to Excellent Management and Disclosure of Human Capital Initiatives
February 20 2024 08:35 JST
 
Eisai: Metoject Subcutaneous Injection Pen (Methotrexate) Pen-Type Autoinjector Approved in Japan
February 16 2024 08:31 JST
 
Eisai Commences Fully-Fledged Business Activities at Pharma Sales Subsidiary in South Africa
February 01 2024 17:04 JST
 
Eisai Submits New Drug Application for Mecobalamin Ultrahigh-Dose Formulation in Japan for the Indication of Amyotrophic Lateral Sclerosis
January 26 2024 15:26 JST
 
Eisai: Antiepileptic Drug Fycompa Injection Formulation Approved in Japan
January 18 2024 14:12 JST
 
Eisai Listed as a Global 100 Most Sustainable Corporation for the Eighth Time
January 17 2024 16:08 JST
 
Eisai Furthers Oncology Research Across Multiple Cancers at ASCO GI and ASCO GU 2024
January 16 2024 09:25 JST
 
Eisai: The Scientific Advisory Group (SAG) to Convene to Discuss the Marketing Authorization Application for lecanemab in the EU
January 11 2024 15:33 JST
 
Eisai: "LEQEMBI" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in China
January 10 2024 09:15 JST
 
More Press release >>

Latest Press Release


More Latest Release >>